Short answer
Definium Therapeutics, Inc. (DFTX) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$77M
- −230.2% YoY
- EPS (diluted)
- −$0.71
- −102.9% YoY
Source: XBRL data from the Definium Therapeutics, Inc. (DFTX) Q1 2026 10-Q on SEC EDGAR. USD.
Definium Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product candidates commercialized
- Net loss $77.1M vs $23.3M YoY; operating loss $59.2M vs $32.2M
- R&D expense $41.5M, up 78% YoY; DT120 program highest at $29.3M
- Cash, equivalents and investments $373.4M; working capital $299.5M at March 31, 2026
- Cash runway into 2028; Phase 3 readouts expected Q2–Q3 2026, with additional capital required
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Definium Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.